Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Uz, B., Bektas, O., Eliacık, E., Goker, H., Erbilgin, Y., Sayitoglu, M., Sayinalp, N., Aksu, S., Buyukasik, Y., Ozcebe, O., Haznedaroglu, I. C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2011
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3420724/
https://ncbi.nlm.nih.gov/pubmed/22937303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/263725
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi